• linkedin
  • Increase Font
  • Sharebar

    New adjunctive treatment for partial-onset seizures

    Eslicarbazepine acetate (Aptiom, Sunovion Pharmaceuticals, Inc) was approved by the FDA on November 8, 2013 as an adjunctive treatment of partial-onset seizures in adults. A pro-drug, after oral administration, eslicarbazepine acetate is extensively metabolized via first pass metabolism to the major active metabolite, eslicarbazepine. Eslicarbazepine is a voltage-gated sodium channel inhibitor. 

    Kathryn Wheeler, PharmD, BCPS
    Kathryn Wheeler, PharmD, BCPS, is assistant clinical professor of pharmacy practice, University of Connecticut School of Pharmacy, ...

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available